Palbociclib

Description

Palbociclib · CAS 571190-30-2 · C24H29N7O2. UNII G9ZF61LE7G. Boiling Point: 711.5; Melting Point: 263-266 ºC; Solubility: 10.

Identification

Computed Descriptors

Physical & Chemical Properties

Physical description & handling notes

• 7.4 (the secondary piperazine nitrogen) and 3.9 (the pyridine nitrogen)

GHS Hazard Classification

Documented Uses

• Palbociclib is indicated in combination with [letrozole] as initial endocrine-based therapy for the treatment of human epidermal growth factor receptor type 2 (HER2)-negative and hormone receptor(HR)-positive tumors in adult patients with advanced/metastatic breast cancer. It is as well approved in combination with [fulvestrant] in patients with disease progression with prior endocrine therapy. In the official labeling, the use of palbociclib should be accompanied with either an aromatase inhibition, no restricted
• Palbociclib is a unique cyclin-dependent kinase inhibitor that is used in combination with aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer. Palbociclib is associated with transient and usually mild elevations in serum aminotransferase during therapy and to an unusual form of liver injury called pseudocirrhosis caused by shrinkage of tumor metastases in the liver combined with desmoplastic changes and vascular damage, that can be severe, progressive and even fatal.
• Breast Feeding; Lactation; Milk, Human; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors
• Palbociclib is approved to be used with other drugs to treat:
• • Breast cancer that is hormone receptor positive (HR+) and HER2 negative (HER2-) and has spread. It is used:
• • with fulvestrant in adults whose cancer has gotten worse after treatment with hormone therapy

Synonyms

Palbociclib; 571190-30-2; Ibrance; PD-0332991; PD0332991; PD 0332991; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; CHEBI:85993; DTXSID40972590; 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one; Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-

Frequently Asked Questions

What are the CAS number and molecular formula of Palbociclib?

CAS 571190-30-2; molecular formula C24H29N7O2; molecular weight — g/mol.

What other names is Palbociclib known by?

Palbociclib, 571190-30-2, Ibrance, PD-0332991, PD0332991, PD 0332991.

Is Palbociclib classified as hazardous?

Hazard statements reported: H301, H341, H360, H373, H411.

What are the key physical properties of Palbociclib?

Boiling Point: 711.5; Melting Point: 263-266 ºC; Solubility: 10; LogP: 0.99.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.